Should statisticians reporting to data monitoring committees be independent of the trial sponsor and leadership?
- 27 April 2004
- journal article
- research article
- Published by Wiley in Statistics in Medicine
- Vol. 23 (10), 1503-1505
- https://doi.org/10.1002/sim.1784
Abstract
It has long been a fundamental principle of clinical trials that interim comparative data should be kept confidential, with such data accessible only to a small number of individuals responsible for its analysis and monitoring. The rationale for keeping investigators and sponsors blinded to interim data has been extensively discussed, but the possible conflicts of interest that could arise for the statistician who performs the analysis of the interim data and presents it to a data monitoring committee has received little attention. We describe these potential conflicts, and the advantages and disadvantages of approaches that might be taken to minimize them. We have invited commentary on this issue from several statisticians with substantial experience in clinical trials and interim data monitoring. Published in 2004 by John Wiley & Sons, Ltd.Keywords
This publication has 9 references indexed in Scilit:
- Monitoring clinical trials: issues and controversies regarding confidentialityStatistics in Medicine, 2002
- Data Monitoring Committees in Clinical TrialsPublished by Wiley ,2002
- Terms of reference for Data and Safety Monitoring CommitteesAmerican Heart Journal, 2001
- Procedures of Data and Safety Monitoring CommitteesAmerican Heart Journal, 2001
- Clinical Trials and Treatment Effects MonitoringControlled Clinical Trials, 1998
- Some practical aspects of the interim monitoring of clinical trialsStatistics in Medicine, 1994
- Monitoring of clinical trials: Issues and recommendationsControlled Clinical Trials, 1993
- Some FDA perspectives on data monitoring in clinical trials in drug developmentStatistics in Medicine, 1993
- Policies for study monitoring and interim reporting of results.Journal of Clinical Oncology, 1987